Pharmaceuticals
10 Johnson & Johnson business development leaders
These ten current and former Johnson & Johnson business development leaders have held director, senior director, head and vice president roles in licensing and M&A, search and evaluation, transactions and alliance management at Johnson & Johnson. A reader can learn how business development leaders work at Johnson & Johnson from people who have held the role.
Professionals to explore
01—10Andrew T. Hutchinson
LinkedInExperience: Senior Director, Acquisitions, Immunology - Business Development · Johnson & Johnson Innovative Medicine
Senior Director, Acquisitions, Immunology - Business Development at Johnson & Johnson Innovative Medicine since June 2022. He was previously Director, Global Head of Immunology Business Development & Licensing at Boehringer Ingelheim (2018–2022) and Senior Manager, External Research & Scouting at Alexion Pharmaceuticals.
Catherine Caicedo
LinkedInExperience: Senior Director, Business Development, Immunology · Johnson & Johnson Innovative Medicine
Senior Director, Business Development, Immunology at Johnson & Johnson Innovative Medicine since April 2024, a role her headline describes as licensing and M&A in immunology. She was Director, Janssen Business Development (2019–2024), after finance roles across Janssen, McNeil Consumer Healthcare and Mentor Worldwide.
Charlie Knights
LinkedInExperience: Senior Director, Business Development, Immunology · Johnson & Johnson
Senior Director, Business Development, Immunology at Johnson & Johnson since January 2023, a role his headline describes as licensing and M&A in immunology. He previously led business development for precision medicine and data sciences at J&J as Director and then Senior Director (2018–2023), after finance roles supporting business development and JLABS.
Chris Dancer
LinkedInExperience: Sr. Director, Business Development Transactions - Oncology · Johnson & Johnson
Sr. Director, Business Development Transactions - Oncology at Johnson & Johnson since May 2026, after serving as Director in the same group from 2024; his profile describes leading cross-functional teams to evaluate, negotiate and execute licensing and M&A transactions. He was earlier a finance manager for venture capital investments at J&J (2018–2024).
Joerg Laeuffer
LinkedInExperience: Senior Director Business Development · Johnson & Johnson
Senior Director Business Development at Johnson & Johnson since November 2023 and Senior Director Search & Evaluation at Johnson & Johnson Innovative Medicine since 2020, based in Switzerland; his profile describes identifying new external opportunities for evaluation in line with J&J Innovative Medicine strategy. He was earlier Senior Director Search & Evaluation at Actelion.
Kara Bortone
LinkedInExperience: Senior Director, J&J Innovative Medicine Business Development · Johnson & Johnson
Senior Director, J&J Innovative Medicine Business Development since April 2021, where her profile describes leading acquisition, licensing and partnership diligence and transactions in precision medicine. She earlier led sourcing and portfolio management at Johnson & Johnson Innovation, JLABS and was Head of JLABS San Diego (2017–2019).
Lisa Daly Norquay
LinkedInExperience: Senior Director, Business Development, Cardiovascular, Metabolism, and Ophthalmology · Johnson & Johnson Innovative Medicine
Senior Director, Business Development, Cardiovascular, Metabolism, and Ophthalmology at Johnson & Johnson Innovative Medicine since November 2023; her profile describes a scientific licensing role focused on mid- and late-stage partnerships with established pharmaceutical and biotechnology companies. She was earlier Senior Director, Janssen Business Development (2020–2023) and a scientific director in Janssen R&D.
Monica Cheng
LinkedInExperience: Head of Divestitures - Business Development · Johnson & Johnson Innovative Medicine
Head of Divestitures - Business Development at Johnson & Johnson Innovative Medicine since November 2025, and Senior Director, Business Development - Cardiovascular, Metabolism and Retina since 2021. She was earlier Deputy Head - Business Development & Licensing - Cardiometabolic Diseases at Boehringer Ingelheim (2015–2021).
Patrick Benz
LinkedInExperience: Senior Director Alliance Management · Johnson & Johnson Innovative Medicine
Senior Director Alliance Management at Johnson & Johnson Innovative Medicine since September 2013, based in Zurich, after serving as Senior Director Licensing & New Business Development at Johnson & Johnson (2008–2013). He earlier held commercial roles at J&J, including EMEA Franchise Leader Strategic Marketing and Business Unit Director.
Robert J. LaPolla
LinkedInExperience: Vice President Licensing and Business Development · Johnson & Johnson
Former Vice President Licensing and Business Development at Johnson & Johnson (2004–2012), now retired, after serving as Executive Director (2000–2004) and Director (1991–2000) of Licensing and Business Development at J&J. His profile lists experience across stem cells, biomarkers, translational medicine, CNS, cardiovascular, metabolic and virology.
Choose the right perspective
Match the person's scope to your question, since search and evaluation, licensing and acquisitions by therapeutic area, deal transactions, divestitures and alliance management involve different work. Check whether the person's role is current or former and which therapeutic area it covers, since both shape what they can speak to.
Questions to take into the conversation
- 01How does a large healthcare company organize licensing and M&A teams by therapeutic area?
- 02How are external opportunities screened before a deal team is formed?
- 03How does alliance management work after a licensing deal is signed?
Reaching Johnson & Johnson business development leaders
How can I contact one of these Johnson & Johnson business development leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 2 companies: Johnson & Johnson Innovative Medicine and Johnson & Johnson, based on profile data retrieved on October 9, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Johnson & Johnson business development leaders?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Johnson & Johnson business development leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal